Cancer oncogenes

Bialkowska A.B. Crisp M. Bannister T. He Y. Chowdhury S. Schurer S. Chase P. Spicer T. Madoux F. Tian C. Hodder P. Zaharevitz D. Yang, V.W. Identification of small-molecule inhibitors of the colorectal cancer oncogene Kriippel-like factor 5 expression by ultrahigh-throughput screening. Molecular Cancer Therapeutics, 2011, 10, 2043-2051. 

Nagar S, Remmel RP (2006) Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25 1659-1672... 

Rosell R, Scagliotti G, Danenberg KD et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003 22 3548-3553. 

Takahashi T, Haruki N, Nomoto S et al. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 1999 18 4295 300. 

Jiang W, Kahn SM, Guillem JG, Lu SH, Weinstein IB (1989) Rapid detection of ras oncogenes in human tumors applications to colon, esophageal, and gastric cancer. Oncogene 4 923-928... 

Pegram M, Hsu S, Lewis G, Pietras R. 1999. Inhibitory effects of combination of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancer. Oncogene. 18 2241-2251. 

Rao, G.N., Ney, E., and Herbert, R.A. 2000. Effect of Melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res. Treat. 64,... 

Lemoine, N. R., Staddon, S., Dickson, C., Barnes, D. M., and Gullick, W. J. (1990). Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 5, 237-239. 

Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., and Slamon, D. (1999). Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241-2251. 

Wang ZH, Shen B, Yao HL, Jia YC, Ren J, Feng YJ, Wang YZ (2007) Blockage of intermediate-conductance-Ca2+-activated K+ channels inhibits progression of human endometrial cancer. Oncogene 26 5107-5114... 

C5. Carstens, R. P., Eaton, J. V., Krigman, H. R., Walther, P. J., and Garcia-Bianco, M. A., Alternative splicing of fibroblast growth factor receptor 2 (FGF-R-2) in human prostate cancer. Oncogene 15, 3059-3065 (1997). 

Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of 68. disease evolution in human cancer. Oncogene 2007 7 441-453. 

Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen- 69. activated protein kinase cascade for the treatment of cancer. Oncogene 2007 26 3291-3310. 

Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26 3279-3290... 

Soder, A., Hoare, S., Muir, S., Going, J., Parkinson, E., and Keith, W. (1997) Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 14,1013-1021. 

Knudson AG Jr. Hereditary cancer, oncogenes, and anti-oncogenes. Cancer Res 1985 45 1437-81,... 

Bastian, B. C. 2003. Understanding the progression of melanocytic neoplasia using genomic analysis From fields to cancer. Oncogene 22 3081-6. 

Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRKl are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004 23 7426-7440. 

Pfeifer, G.P., Denissenko, M.F., Olivier, M., Tretyakova, N., Hecht, S.S., and Hainaut, P. (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene, 21, 7435-7451. 

Ji, P., Diederichs, S., Wang, W, et al. 2003. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22, 8031-8041. 

---